X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs STERLING BIOTECH - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD STERLING BIOTECH WYETH LTD/
STERLING BIOTECH
 
P/E (TTM) x 27.7 -1.6 - View Chart
P/BV x 5.3 0.1 8,403.8% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   STERLING BIOTECH
EQUITY SHARE DATA
    WYETH LTD
Mar-13
STERLING BIOTECH
Dec-13
WYETH LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,04411 9,946.7%   
Low Rs8183 24,058.8%   
Sales per share (Unadj.) Rs298.626.8 1,113.8%  
Earnings per share (Unadj.) Rs57.2-15.0 -382.7%  
Cash flow per share (Unadj.) Rs58.4-5.5 -1,069.3%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.554.9 454.6%  
Shares outstanding (eoy) m22.72267.87 8.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.10.3 1,203.0%   
Avg P/E ratio x16.3-0.5 -3,501.0%  
P/CF ratio (eoy) x15.9-1.3 -1,253.1%  
Price / Book Value ratio x3.70.1 2,947.6%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,1571,862 1,136.4%   
No. of employees `0000.51.4 36.3%   
Total wages/salary Rs m400547 73.2%   
Avg. sales/employee Rs Th13,787.45,303.3 260.0%   
Avg. wages/employee Rs Th813.0403.8 201.3%   
Avg. net profit/employee Rs Th2,643.3-2,959.0 -89.3%   
INCOME DATA
Net Sales Rs m6,7837,181 94.5%  
Other income Rs m35343 827.7%   
Total revenues Rs m7,1367,223 98.8%   
Gross profit Rs m1,617947 170.8%  
Depreciation Rs m272,543 1.0%   
Interest Rs m64,377 0.1%   
Profit before tax Rs m1,938-5,931 -32.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m632-1,924 -32.9%   
Profit after tax Rs m1,301-4,007 -32.5%  
Gross profit margin %23.813.2 180.8%  
Effective tax rate %32.632.4 100.6%   
Net profit margin %19.2-55.8 -34.4%  
BALANCE SHEET DATA
Current assets Rs m6,98414,335 48.7%   
Current liabilities Rs m2,05649,809 4.1%   
Net working cap to sales %72.6-494.0 -14.7%  
Current ratio x3.40.3 1,180.4%  
Inventory Days Days99403 24.6%  
Debtors Days Days24171 14.0%  
Net fixed assets Rs m24455,432 0.4%   
Share capital Rs m227268 84.8%   
"Free" reserves Rs m5,44113,935 39.0%   
Net worth Rs m5,66814,701 38.6%   
Long term debt Rs m259,478 0.3%   
Total assets Rs m7,90173,988 10.7%  
Interest coverage x353.3-0.4 -99,539.7%   
Debt to equity ratio x00.6 0.7%  
Sales to assets ratio x0.90.1 884.6%   
Return on assets %16.50.5 3,300.0%  
Return on equity %22.9-27.3 -84.2%  
Return on capital %34.0-6.4 -529.8%  
Exports to sales %0.225.9 0.8%   
Imports to sales %36.30.2 21,391.8%   
Exports (fob) Rs m151,860 0.8%   
Imports (cif) Rs m2,46512 20,208.2%   
Fx inflow Rs m151,860 0.8%   
Fx outflow Rs m2,67725 10,756.1%   
Net fx Rs m-2,6621,835 -145.1%   
CASH FLOW
From Operations Rs m9231,719 53.7%  
From Investments Rs m317-3,148 -10.1%  
From Financial Activity Rs m-4811,426 -33.7%  
Net Cashflow Rs m759-3 -22,326.5%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 0.0 -  
FIIs % 7.2 9.9 72.7%  
ADR/GDR % 0.0 16.9 -  
Free float % 30.4 39.3 77.4%  
Shareholders   21,978 21,482 102.3%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   PIRAMAL ENTERPRISES  NOVARTIS  TTK HEALTHCARE  ALKEM LABORATORIES  BIOCON LTD  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - DISHMAN PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS